Incyte stock analysis: INCY grows revenue 37.7% at a 15.46 P/E with a 98/100 Quality score. Why the model rates it a Buy despite the 2028 Jakafi cliff.
fundamental analysis
-
-
FeaturedPharmaceuticalsUS Stocks
United Therapeutics Rallies on Its Tyvaso IPF Filing – a 95/100 Quality Score at 19.4 Times Earnings
United Therapeutics stock analysis: UTHR rallies on its Tyvaso IPF filing with a 95/100 Quality score and a 19.40 P/E. Why the model rates it a Buy.
-
Food & BeverageUS Stocks
PepsiCo Sinks to a Two-Year Low on a 16.87 P/E and 4.6% Yield – Yet the Model Stops Short of Buy
PepsiCo stock analysis: PEP hits a two-year low on a 16.87 P/E and 4.6% dividend yield. Why leverage and slow growth keep the model at Hold.
-
Renewable UtilitiesUS Stocks
Fervo Energy Hits a Two-Year Low Days After Its Cape Station Geothermal Plant Reached First Power
Fervo Energy Company stock analysis: FRVO hits its two-year low days after Cape Station’s first power. Liquidity, losses and valuation explained.
-
FeaturedSoftwareUS Stocks
PicPay Parent PicS N.V. Sits at Its Two-Year Low Despite 67% Revenue Growth
PicS N.V. stock analysis: PicPay’s parent grew revenue 67% yet trades at a two-year low. Quality, growth and valuation scores explained.
-
HardwareUS Stocks
Viavi Solutions: Revenue Up 52.5%, but a 36x EV/EBITDA Multiple Keeps the Signal at Hold
Viavi Solutions stock analysis: revenue up 52.5% and a 60.9% gross margin, but a net loss and 36x EV/EBITDA keep VIAV at Hold.
-
FeaturedMedia & EntertainmentUS Stocks
Fox Corporation: Modest Multiples and a Strong Balance Sheet Put It Right at the Buy Line
Fox Corporation stock analysis: a 25.2% operating margin, strong liquidity and 7.7x EV/EBITDA put FOXA right at the model’s Buy line.